Table 1.
Overview of reviewed clinical trials
| ACT varianta | Cancer type | N | %OR | Outcome (CR/PR/SD/AD) | Reference |
|---|---|---|---|---|---|
| TILs | Melanoma | 93 | 56 | 19 CR, 33 PR | (Rosenberg et al. 2011) |
| TILs | Melanoma | 101 | 54 | 23 CR, 30 PR | (Goff et al. 2016) |
| TILs, single neo-epitope enriched | Gastro-intestinal | 4 | 50 | 1CR, 1 PR | (Tran et al. 2015) |
| TILs reactive to HPV | Cervical | 9 | 33 | 2 CR, 1 PR | (Stevanović et al. 2015) |
| EBV-specific CTLs from cell lines | Lymphoma | 13 | 85 | 11 CR | (Heslop et al. 2010) |
| DC vaccine primed PBLs | Ovarian | 3 | 66 | 1 CR, 1 SD | (Kandalaft et al. 2013) |
| HER2/neu vaccine primed PBLs | HER2+ breast and ovarian | 7 | 43 | 3 PR | (Disis et al. 2014) |
| PBLs w/ engin. CEA reactive TCR |
colon | 3 | 33 | 1 PR 3 AD severe inflammatory colitis |
(Parkhurst et al. 2011) |
| PBLs w/ engin. MAGE-A3 reactive TCR |
MAGE-A3/12+ tumours | 9 | 55 | 1 CR, 4 PR 3 AD neurotoxicity (two deaths) |
(Morgan et al. 2013) |
| PBLs w/ engin. NY-ESO-1 reactive TCR |
Melanoma | 20 | 55 | 4 CR, 7 PR | (Robbins et al. 2015) |
| PBLs w/ engin. NY-ESO-1 reactive TCR |
Synovial cell sarcoma | 18 | 61 | 1 CR, 10 PR | (Robbins et al. 2015) |
TAAs: carcinoembryonic antigen (CEA) New York esophageal squamous cell carcinoma-1 (NY-ESO-1), human epidermal growth factor receptor 2 (HER2/neu), and melanoma-associated antigen (MAGE). Epstein-Barr virus (EBV) human papillomavirus (HPV). RECIST criteria were used for describing outcome: complete response (CR), partial response (PR), objective response (OR) both CR and PR. Stable disease (SD), adverse effects (AD). We have chosen not to indicate the patients that eventually progress to disease, as this heavily depends on the follow-up time of the cohorts
aTumour infiltrating lymphocyte (TIL), peripheral blood lymphocyte (PBL), cytotoxic T lymphocyte (CTL), T cell receptor (TCR), tumour-associated antigen (TAA), and dendritic cell (DC). N is the number of patients